Icon Plc (ICLR) Receives $125.40 Consensus Target Price from Analysts
Shares of Icon Plc (NASDAQ:ICLR) have been assigned an average rating of “Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $125.40.
A number of brokerages have issued reports on ICLR. Credit Suisse Group raised Icon to a “buy” rating and set a $131.00 target price for the company in a research report on Friday, February 16th. Mizuho reiterated a “neutral” rating and set a $114.00 price target (up from $109.00) on shares of Icon in a report on Thursday, February 15th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. BidaskClub upgraded Icon from a “strong sell” rating to a “sell” rating in a report on Friday, February 9th. Finally, SunTrust Banks reiterated a “buy” rating and set a $133.00 price target on shares of Icon in a report on Monday, January 22nd.
Shares of Icon (NASDAQ:ICLR) traded up $1.94 during trading on Wednesday, reaching $115.11. The company’s stock had a trading volume of 402,370 shares, compared to its average volume of 358,101. The company has a market capitalization of $6,128.38, a PE ratio of 22.44, a P/E/G ratio of 1.61 and a beta of 0.45. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a 52-week low of $76.46 and a 52-week high of $124.48.
Hedge funds have recently modified their holdings of the company. Insight Capital Research & Management Inc. acquired a new position in shares of Icon during the third quarter worth approximately $1,359,000. BT Investment Management Ltd acquired a new position in shares of Icon in the third quarter valued at $325,000. JPMorgan Chase & Co. raised its stake in shares of Icon by 11.5% in the third quarter. JPMorgan Chase & Co. now owns 42,043 shares of the medical research company’s stock valued at $4,697,000 after purchasing an additional 4,320 shares in the last quarter. NorthCoast Asset Management LLC raised its stake in shares of Icon by 23.4% in the third quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 3,419 shares in the last quarter. Finally, Palisade Capital Management LLC NJ raised its stake in shares of Icon by 1.9% in the third quarter. Palisade Capital Management LLC NJ now owns 253,768 shares of the medical research company’s stock valued at $28,899,000 after purchasing an additional 4,702 shares in the last quarter. Institutional investors own 89.18% of the company’s stock.
WARNING: “Icon Plc (ICLR) Receives $125.40 Consensus Target Price from Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2018/03/03/icon-plc-iclr-receives-125-40-consensus-target-price-from-analysts.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.